7. OncoGenex Pharmaceuticals (OGXI) develops and commercializes cancer therapies. It swung to a second-quarter profit of $150,000, or 2 cents a share, from a year-earlier loss. Revenue turned positive, hitting $1.7 million. OncoGenex has $48 million of cash and $51 million of debt. Its stock trades at a sales multiple of 3.7 and a cash flow multiple of 4.6, 96% and 75% discounts to pharmaceutical industry averages. All eight analysts following the company rate its stock "buy." A median target of $48.17 suggests a 12-month gain of 156%.
Bullish Scenario: Rodman & Renshaw (RODM) predicts the stock will more than triple to $58.